Back to search

Article

Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemia

2023-01-27

Abstract excerpt

<title>Abstract</title> <p>Hypomethylating agents (HMAs) including azacitidine (AZA) represent the only FDA-approved first-line treatments for patients with chronic myelomonocytic leukemia (CMML). However, the mechanism by which HMAs produce therapeutic responses (e.g., hematological improvement) remains unclear. Bone marrow mesenchymal stromal cells (MSCs) play a crucial role in regulating the self-renewal, surv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
47cdc2b3-5e69-5059-842c-c539e60c453f
DOI
10.21203/rs.3.rs-2475679/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaDOI 10.21203/rs.3.rs-2475679/v1
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesisSemantic proximity
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.Semantic proximity
Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalSemantic proximity
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomeSemantic proximity
Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingSemantic proximity
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity
The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsSemantic proximity
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.Semantic proximity
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.